Osmotica Pharmaceuticals (OSMT) Upgraded by Zacks Investment Research to “Hold”

Share on StockTwits

Zacks Investment Research upgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a sell rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Separately, Wells Fargo & Co set a $14.00 price target on Osmotica Pharmaceuticals and gave the stock a buy rating in a report on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $15.50.

NASDAQ OSMT traded up $0.03 on Tuesday, reaching $2.70. The company had a trading volume of 22,509 shares, compared to its average volume of 293,207. The stock has a market cap of $130.35 million and a PE ratio of -5.29. Osmotica Pharmaceuticals has a 1 year low of $2.40 and a 1 year high of $9.90. The company has a quick ratio of 1.29, a current ratio of 1.70 and a debt-to-equity ratio of 0.71.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.08). The business had revenue of $57.13 million during the quarter, compared to analysts’ expectations of $53.58 million. Sell-side analysts anticipate that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in OSMT. SG Americas Securities LLC bought a new position in Osmotica Pharmaceuticals during the first quarter worth $45,000. American International Group Inc. bought a new position in Osmotica Pharmaceuticals during the fourth quarter worth $50,000. Acadian Asset Management LLC bought a new position in Osmotica Pharmaceuticals during the first quarter worth $52,000. Hancock Whitney Corp bought a new position in Osmotica Pharmaceuticals during the first quarter worth $83,000. Finally, Deutsche Bank AG bought a new position in Osmotica Pharmaceuticals during the fourth quarter worth $111,000. Institutional investors own 12.78% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.